ClinicalTrials.gg
CompletedNCT05836220PATH-2Updated Sep 9, 2025

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

A Phase 3 interventional study of PLS240 and Placebo in Secondary Hyperparathyroidism and End Stage Kidney Disease, sponsored by Pathalys Pharma. Completed at 68 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Pathalys Pharma · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
412
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies in Hyperparathyroidism, Secondary with a site in United States — 5 open to participants now, 5 under way, 2 of them phase 3. Hyperparathyroidism, Secondary · United States.

Enrollment
6th of 60
412 · median 43
Started
2023
with 3 others
Phase 3
20 of 66
2 open now
Registered
62nd of 66
by date
Lead sponsor
3 of 66
Pathalys Pharma

Among the 66 studies in Hyperparathyroidism, Secondary with a site in United States, this one is the 6th largest by enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2023, is one of 20 in phase 3, and was the 62nd registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

5 of the 66 studies in Hyperparathyroidism, Secondary with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Hyperparathyroidism, Secondary with a site in United States, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.

03

Conditions studied

  • Secondary Hyperparathyroidism
  • End Stage Kidney Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 - 80 years at time of .
  2. Prescribed hemodialysis for 3 times per week and on therapy for at least 3 months and has a delivered Kt/V≥1.2 within 4 weeks prior to signing the ICF.
  3. Pre-dialysis central laboratory iPTH must be ≥400 pg/mL on at least two assessments performed at 2 visits, at least 1 week apart during the Active Screening period. iPTH may be tested up to 4 times.

    at least performed at least a week after the previous iPTH.

  4. Pre-dialysis central laboratory cCa must be ≥8.3 mg/dL on at least one assessment performed during the Active Screening period. cCa may be tested up to 3 times during the Active Screening period.
  5. Dialysate calcium concentration ≥2.5 mEq/L (1.25 mmol/L) and stable for at least 4 weeks prior to signing the ICF.
  6. Participants receiving active Vitamin D sterols (e.g., doxercalciferol or calcitriol) to manage SHPT must be on a stable dose (e.g., maximum dose change ≤50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF, remain stable, as defined as no increase in dose, through the screening period, and be expected to maintain a stable dose, as defined as no increase in dose, for the duration of the study.
  7. Participants receiving phosphate binders must be on a stable dose (e.g., maximum dose change ≤50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF, remain stable through the screening period, and be expected to maintain stable dose for the duration of the study.
  8. Participants receiving calcium supplements must be on a stable dose (e.g., maximum dose change ≤50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF and remain stable through the screening period.
  9. Female participants who are ('post-menopausal' women have had no menses for the previous year and are over the age of 50 years), or surgically sterilized, or have a medical condition that prevents pregnancy, or commit to remain abstinent during the study and for 2 weeks after the last dose of the product (IP), or are willing to use highly effective during the study and for 2 weeks after the last dose of IP. Women of must have a negative serum pregnancy test during the screening period.
  10. Male participants who are willing to use highly effective contraception when sexually active and will not donate sperm during the treatment phase and for 2 weeks after the last dose of IP.
  11. Voluntarily given written informed consent to participate in this study.
  12. Agrees to not participate in another study of an investigational agent during the study

    To be eligible for inclusion into the Open-Label Extension Phase of the study, participants must fulfill the additional following criteria at the time of entry into the Open-Label Extension Phase:

  13. Have successfully completed the course of treatment and final safety follow-up visit of the Double-Blind Phase.
  14. Voluntarily given written informed consent to participate in the Open-Label Extension Phase of the study.
  15. Prescribed hemodialysis for 3 times per week. 16. Continue to meet Inclusion Criteria 9, 10, and 12.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary hyperparathyroidism.
  2. Pre-dialysis central laboratory Active Screening iPTH >1500 pg/mL on two or more occasions. iPTH may be tested up to 4 times during the Active Screening period.
  3. History of parathyroid intervention including parathyroidectomy (PTx) and percutaneous ethanol injection therapy (PEIT) within 26 weeks before signing the ICF.
  4. Treatment with any prohibited medication as defined in Section 8.3.1.
  5. Anticipated or scheduled parathyroidectomy during the study period.
  6. Planned living-related or living-unrelated kidney transplant during the study period.
  7. Change in mode of dialysis (e.g., from hemodialysis to hemodiafiltration, peritoneal dialysis to hemodialysis, at home to in center dialysis), dialysate Ca concentration, or prescribed dialysis treatment time within 4 weeks before signing the ICF.
  8. Noncompliant with hemodialysis (i.e., missing more than 2 dialysis sessions within 8 weeks prior to signing the ICF, unless absence is due to hospitalization or dialysis-access procedures).
  9. abnormalities on screening laboratory tests (may repeat abnormal laboratory tests) according to the Investigator including but not limited to the following:

    1. Serum albumin ≤3.0 g/dL
    2. Serum magnesium \<1.5 mg/dL
    3. Serum P >8.0 mg/dL
    4. \<8.5 g/dL
    5. count \<100,000 x106/L
    6. Serum transaminase ( [ALT] or serum glutamic pyruvic transaminase [SGPT], alanine transaminase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) ≥2.5 times the (ULN) during Active Screening.
  10. Diagnosed with an unstable medical condition, defined as having been hospitalized, other than for dialysis vascular access intervention, within 30 days prior to signing the TCF, or otherwise unstable in the judgment of the investigator.
  11. History of within the last 2 years prior to signing the ICF (except squamous or basal cell skin cancers, or cervical carcinoma in situ).
  12. Recent history (within 4 weeks prior to signing the ICF) of angina pectoris with symptoms that occur at rest or minimal activity. Chest pain on dialysis (within 8 weeks prior to signing the ICF) unless evaluated by a cardiologist with documentation that the chest pain is not due to cardiac ischemia.
  13. History of (NYHA) Functional Class 3 or 4 heart failure.
  14. History of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 4 months prior to signing the ICF.
  15. Stroke (cerebral infarction or cerebral hemorrhage) within 6 months prior to signing the ICF.
  16. Participant is receiving treatment for a seizure disorder or has a history of a seizure within 12 weeks prior to signing the ICF.
  17. Poorly controlled diabetes mellitus, in the judgment of the investigator or sub-investigator.
  18. Poorly controlled hypertension (defined as post-dialysis [seated if available] systolic pressure >180 mmHg or diastolic pressure >110 mmHg) at 2 or more dialysis sessions during the 2 weeks prior to signing the ICF.
  19. Enrolled in other invasive device or investigational drug trials, within at least 30 days prior to signing the ICF or are receiving other investigational agents (experimental dialysis machines are acceptable).
  20. History of symptomatic ventricular dysrhythmias or Torsade de Pointes.
  21. History of or family history of long syndrome.
  22. QTcF >500 msec on screening .
  23. Pregnant or breast feeding.
  24. Prior exposure or to PLS240 or any of its components.
  25. Current, recent, or suspected infection with SARS-CoV-2/COVID-19 within 4 weeks prior to signing the ICF.
  26. In the opinion of the investigator, any disorder that would interfere with understanding and giving , or compliance with protocol requirements.

    Participants must be excluded from the Open-Label Extension Phase of the study, in case of the following at the time of entry into the Open-Label Extension Phase:

  27. In the opinion of the investigator, continuation into the Open-Label Extension Phase is not considered safe and/or feasible.
  28. Continues to meet Exclusion Criterion #5.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
412 participants (actual)

Study arms

  • Experimental
    Double-Blind Phase PLS240

    Drug: PLS240

  • Placebo comparator
    Double-Blind Phase Placebo

    Drug: Placebo

  • Experimental
    Open-Label Extension Phase PLS240

    After completion of the Double-Blind Phase, all participants will have the opportunity to enroll in the 26 week Open-Label extension, where they will receive PLS240.

    Drug: Open-Label Extension PLS240

Interventions

  • DrugPLS240

    Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.

  • DrugPlacebo

    Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.

  • DrugOpen-Label Extension PLS240

    Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.

06

What researchers measure

Primary outcomes

  1. The proportion of PLS240 treated participants compared to the portion of placebo treated participants with a ≥30% decrease in mean iPTH

    Double-Blind Phase only. This measurement will be calculated based on the Efficacy Assessment Period (Weeks 22 - 27) relative to the mean baseline iPTH (all Active Screening and predose Day 1 iPTH values).

    Time frame: each visit from screening through week 27

  2. Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dL

    Time frame: up to week 28

  3. Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dL

    Time frame: up to week 28

  4. Open-Label Phase: Number of AE's

    Time frame: up to week 28

  5. Open-Label Phase: Number of SAE's

    Time frame: up to week 28

07

Study locations

68 sites
  • Site Number: USA039-2
    Anaheim, California 92801-6731, United States
  • Site Number: USA001-2
    Chula Vista, California 91910-3813, United States
  • Site Number: USA020-2
    Escondido, California 92025-4402, United States
  • Site Number: USA042-2
    Fresno, California 93720-3389, United States
  • Site Number: USA034-2
    Fullerton, California 92832-3037, United States
  • Site Number: USA046-2
    Glendale, California 91205-3313, United States
  • Site Number: USA019-2
    Granada Hills, California 91344-7407, United States
  • Site Number: USA005-2
    La Mesa, California 91942-3017, United States
  • Site Number: USA044-2
    Lancaster, California 93534-2831, United States
  • Site Number: USA030-2
    Los Angeles, California 90022-4302, United States
  • Site Number: USA043-2
    Los Angeles, California 90033, United States
  • Site Number: USA022-2
    Moorpark, California 93021-3352, United States
  • Site Number: USA049-2
    Northridge, California 91324-2927, United States
  • Site Number: USA033-2
    Northridge, California 91324-3528, United States
  • Site Number: USA003-2
    San Diego, California 92111-3636, United States
  • Site Number: USA018-2
    San Dimas, California 91773-3539, United States
  • Site Number: USA056-2
    Tarzana, California 91356-2806, United States
  • Site Number: USA021-2
    Tarzana, California 91356-3647, United States
  • Site Number: USA052-2
    Victorville, California 92395-8322, United States
  • Site Number: USA023-2
    Arvada, Colorado 80002-3714, United States
  • Site Number: USA031-2
    Aurora, Colorado 80045-7202, United States
  • Site Number: USA017-2
    Middlebury, Connecticut 06762-2843, United States
  • Site Number: USA015-2
    Newark, Delaware 19713-2081, United States
  • Site Number: USA004-2
    Fort Myers, Florida 33908-4154, United States
  • Site Number: USA002-2
    Hollywood, Florida 33024-2776, United States
  • Site Number: USA041-2
    Orlando, Florida 32801, United States
  • Site Number: USA035-2
    South Miami, Florida 33143-5522, United States
  • Site Number: USA013-2
    Columbus, Georgia 31904-3603, United States
  • Site Number: USA028-2
    Mishawaka, Indiana 46545-3519, United States
  • Site Number: USA024-2
    Wichita, Kansas 67214-2944, United States
  • Site Number: USA054-2
    New Orleans, Louisiana 70112, United States
  • Site Number: USA048-2
    Detroit, Michigan 48236-2169, United States
  • Site Number: USA025-2
    Kalamazoo, Michigan 49007-3889, United States
  • Site Number: USA016-2
    Minneapolis, Minnesota 55404-1212, United States
  • Site Number: USA007-2
    Amherst, New York 14228-2792, United States
  • Site Number: USA053-2
    Charlotte, North Carolina 28208-3876, United States
  • Site Number: USA026-2
    Durham, North Carolina 27704-2147, United States
  • Site Number: USA009-2
    Toledo, Ohio 43606-1171, United States
  • Site Number: USA045-2
    Roseburg, Oregon 97471-6214, United States
  • Site Number: USA010-2
    Greenville, South Carolina 29605-4019, United States
  • Site Number: USA027-2
    Knoxville, Tennessee 37923-3624, United States
  • Site Number: USA011-2
    El Paso, Texas 79925-4828, United States
  • Site Number: USA029-2
    Live Oak, Texas 78233-4767, United States
  • Site Number: USA055-2
    Prosper, Texas 75078-1411, United States
  • Site Number: USA012-2
    San Antonio, Texas 78221-3019, United States
  • Site Number: USA008-2
    San Antonio, Texas 78251-4125, United States
  • Site Number: USA006-2
    Waxahachie, Texas 75165-1399, United States
  • Site Number: USA038-2
    St. George, Utah 84790-5898, United States
  • Site Number: USA051-2
    Fairfax, Virginia 22033-1907, United States
  • Site Number: USA037-2
    Norfolk, Virginia 23507-1901, United States
  • Site Number: BGR003-2
    Lom, Montana 3600, Bulgaria
  • Site Number: BGR001-2
    Gabrovo, 5300, Bulgaria
  • Site Number: BGR002-2
    Rousse, 7002, Bulgaria
  • Site Number: BGR004-2
    Varna, 9000, Bulgaria
  • Site Number: POL002-2
    Poznan, Greater Poland Voivodeship 60-214, Poland
  • Site Number: POL001-2
    Lodz, Lódzkie 90-242, Poland
  • Site Number: POL004-2
    Tomaszów Mazowiecki, Lódzkie 97-200, Poland
  • Site Number: POL005-2
    Warsaw, Masovian Voivodeship 02-758, Poland
  • Site Number: PRT002-2
    Covilha, Castelo Branco District 6200-000, Portugal
  • Site Number: PRT001-2
    Carnaxide, 2790-134, Portugal
  • Site Number: PRT003-2
    Lisbon, 1250-203, Portugal
  • Site Number: SRB005-2
    Belgrade, Belgrade 11080, Serbia
  • Site Number: SRB003-2
    Belgrade, 11000, Serbia
  • Site Number: SRB001-2
    Kruševac, 37000, Serbia
  • Site Number: SRB002-2
    Niš, 18000, Serbia
  • Site Number: SRB004-2
    Užice, 31000, Serbia
  • Site Number: ESP003-2
    Córdoba, Cordoba 14004, Spain
  • Site Number: ESP005-2
    Manises, Valencia 46940, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2025, 26 months.

Of 21 phase 3 interventional studies under Hyperparathyroidism, Secondary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
May 1, 2023
StartActual
May 15, 2023
Primary completionActual
Aug 5, 2025
CompletionActual
Aug 5, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05836220
Lead sponsor
Pathalys Pharma
Collaborators
Launch Therapeutics
Responsible party
Sponsor
First posted
May 1, 2023
Start date
May 15, 2023
Primary completion
Aug 5, 2025
Completion
Aug 5, 2025
Last update
Sep 9, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upacicalcet sodium hydrate

Start the discussion